Field news
An FDA advisory panel narrowly voted to let compounding pharmacies produce popular but unapproved peptides like BPC-157 and KPV. For physicians, this raises real questions about oversight, evidence, and how to counsel patients who ask about these products outside standard regulatory review. Read the original coverage.
Read the source →Field news
The Lantus Solostar pen isn't officially listed as short by the FDA, but patients are reporting real trouble accessing it — a gap between regulatory status and pharmacy-shelf reality. Clinicians managing diabetes care may need to flag alternatives early and document access issues for patients caught in the interim. Details in STAT News.
Read the source →Field news
The European Medicines Agency is taking what advocacy groups call unexpectedly rapid action to force publication of clinical trial results that are legally required to be public. This matters for any physician relying on the evidence base — undisclosed trial data has long been a quiet gap in clinical decision-making. Full story via STAT News / Pharmalot.
Read the source →Help & guides
If you're a licensed physician, you can join our credential verification process to become part of a trusted validator panel — the backbone of everything DataLaps builds. Verified physicians can contribute to Consensus Cases, helping train collective clinical judgment into a defensible dataset that labs and HealthTech teams can actually rely on. You can also join Clinical Room, our moderated discussion space on current clinical topics like today's peptide and insulin stories, or take on Real Training — four clinical tasks per session, each scored against a rubric, to sharpen and document your expertise.
Real metrics, real gaps. We share both.
Audience track: investor